Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen
GSK plc and Arrowhead Pharmaceuticals Inc. today announced that they have reached an agreement with Janssen Pharmaceuticals, Inc.
Download (PDF, 234.7KB) -
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer
Statistically significant and clinically meaningful overall survival benefit observed in the overall population in the trial.
Download (PDF, 503.6KB) -
GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK
GSK to invest £6m in STEM equity-focused initiatives in the UK over ten years to tackle barriers to entry in STEM careers.
Download (PDF, 208.2KB) -
ViiV Healthcare receives approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment
The complete long-acting regimen enables virologically suppressed people living with HIV in China to reduce treatment dosing days.
Download (PDF, 217.9KB) -
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease
Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59.
Download (PDF, 245.6KB) -
GSK enters exclusive license agreement with Hansoh for HS-20089
Hansoh’s HS-20089 complements GSK’s portfolio of gynaecologic cancer therapies.
Download (PDF, 188.0KB) -
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
Key data to be presented include long-term and real-world data, including long-acting and 2-drug regimens.
Download (PDF, 274.3KB) -
GSK highlights new data in non-small cell lung cancer and endometrial cancer at the European Society for Medical Oncology (ESMO) Congress 2023, reinforcing potential of Jemperli (dostarlimab) as a backbone immuno-oncology therapy
Late-breaking data from head-to-head PERLA trial shows favourable numerical trend in overall survival (OS) results
Download (PDF, 691.5KB) -
GSK receives positive CHMP opinion recommending approval of Jemperli (dostarlimab) plus chemotherapy as a new frontline treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Decision on EU marketing authorisation expected by the end of the year.
Download (PDF, 598.6KB) -
GSK presents scientific advances to improve patient outcomes at the American Association for the Study of Liver Diseases’ The Liver Meeting® 2023
New data from the B-Together phase IIb trial contribute to the development of a functional cure for people living with CHB.
Download (PDF, 274.6KB) -
Statement: Zantac (ranitidine) litigation
GSK today confirmed it has reached a confidential settlement in the Cantlay/Harper case filed in California state court.
-
GSK and ViiV Healthcare to present scientific advancements in their industry-leading infectious diseases portfolio at IDWeek 2023
First scientific presentation of RSV vaccine efficacy and safety data over two seasons.
Download (PDF, 347.6KB) -
GSK and Zhifei announce exclusive strategic vaccine partnership in China
Partnership will significantly extend availability of Shingrix in China with co-promotion to healthcare professionals.
Download (PDF, 238.5KB) -
GSK survey finds parents know less about meningitis compared to some other childhood diseases
New multi-country survey finds 93% of parents couldn’t identify all three of the most common meningitis symptoms.
Download (PDF, 233.9KB) -
GSK announces Wendy Becker to join the Board as Non-Executive Director
GSK has announced that Wendy Becker will join the Board of the Company as a Non-Executive Director with effect from 1 October 2023.
Download (PDF, 213.8KB) -
Japan’s Ministry of Health, Labour and Welfare approves GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults
Arexvy’s approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time
Download (PDF, 292.0KB) -
European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention
Cabotegravir demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV in clinical trials.
Download (PDF, 173.0KB) -
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia
Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
Download (PDF, 212.1KB) -
GSK and Save the Children renew award-winning partnership, with focus on ‘zero dose’ children who have never received a vaccine
GSK and Save the Children renew their 10-year partnership for a further five years.
Download (PDF, 153.1KB) -
GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator
Submission included data from trials addressing clinical manifestations of myelofibrosis - splenomegaly, constitutional symptoms and anaemia
Download (PDF, 260.8KB)
